Stock GLMD GALMED PHARMACEUTICALS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Market Closed - Nasdaq
Other stock markets
 21:30:00 10/05/2024 BST 		5-day change 1st Jan Change
0.3983 USD -4.02% Intraday chart for Galmed Pharmaceuticals Ltd. +2.81% -12.46%
04-04 Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-15 Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
PR
Galmed Pharmaceuticals : Consolidated Financial Statements - Form 6-K
PU
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
PR
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
AQ
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
PR
Galmed Pharmaceuticals: Q2 Earnings Snapshot
AQ
Galmed Pharmaceuticals : 16 Tiomkin St. Tel Aviv 6578317, Israel - Form 6-K
PU
Galmed Pharmaceuticals : Securities Purchase Agreement - Form 6-K
PU
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
AQ
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
PR
Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC
PR
Galmed Pharmaceuticals: Q1 Earnings Snapshot
AQ
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
PR
Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt
PR
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol
PR
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement
PR
Galmed Pharmaceuticals: Q3 Earnings Snapshot
AQ
Galmed Pharmaceuticals: Q2 Earnings Snapshot
AQ
Galmed Pharmaceuticals : Provides Business Update and Reports Second Quarter 2022 Financial Results - Form 6-K
PU
Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GLMD Stock
  4. News Galmed Pharmaceuticals Ltd.
  5. Press Releases